Abstract
Previous experiments have demonstrated the stable expression of factor IX (FIX) protein in mice and canine models of hemophilia B following portal vein gene transfer with a recombinant adeno-associated virus (rAAV) vector encoding FIX. Here, we present the results of studies that further optimized the rAAV vector transgene cassette used to express FIX and explored the use of the less-invasive intravenous (i.v.) route of vector administration for the treatment of hemophilia B. First, a liver-specific promoter was evaluated in conjunction with cis-acting regulatory elements in mice. Constructs that included both the β-globin intron and the woodchuck hepatitis virus post-transcriptional regulatory element resulted in the highest level of FIX expression in vivo. Using this optimized vector, we demonstrate that i.v. injection was feasible for hepatic gene transfer in mice, achieving 70–80% of portal vein expression levels of FIX. In further studies using the Chapel Hill strain of hemophilia B dogs, we demonstrate for the first time FIX expression and partial correction of the bleeding disorder following i.v. administration of an AAV vector.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Herzog RW et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 5804–5809.
Snyder RO et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270–276.
Snyder RO et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5: 64–70.
Chao H et al. Persistent expression of canine factor IX in hemophilia B canines. Gene Therapy 1999; 6: 1695–1704.
Wang L et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 1999; 96: 3906–3910.
Wang L et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 2000; 1: 154–158.
Chao H et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619–623.
Nathwani AC et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 2002; 100: 1662–1669.
Kay MA et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257–261.
Ge Y, Powell S, Van Roey M, McArthur JG . Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 2001; 97: 3733–3737.
Nathwani AC et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 2001; 97: 1258–1265.
Herzog RW et al. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 2001; 4: 192–200.
Kay MA et al. A proposed rAAV-liver-directed clinical trial for hemophilia B. Mol Ther 2001; 5: S33 (abstr. 85).
Nakai H, Iwaki Y, Kay MA, Couto LB . Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol 1999; 73: 5438–5447.
Mingozzi F et al. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol 2002; 76: 10497–10502.
Brinster RL et al. Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci USA 1988; 85: 836–840.
Palmiter RD et al. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 1991; 88: 478–482.
Choi T, Huang M, Gorman C, Jaenisch R . A generic intron increases gene expression in transgenic mice. Mol Cell Biol 1991; 11: 3070–3074.
Rodriguez MH et al. Expression of coagulation factor IX in a haematopoietic cell line. Thromb Haemost 2002; 87: 366–373.
Miao CH et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther 2000; 1: 522–532.
Donello JE, Loeb JE, Hope TJ . Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72: 5085–5092.
Zufferey R, Donello JE, Trono D, Hope TJ . Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886–2892.
Loeb JE et al. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther 1999; 10: 2295–2305.
Huang Y, Wimler KM, Carmichael GG . Intronless mRNA transport elements may affect multiple steps of pre-mRNA processing. EMBO J 1999; 18: 1642–1652.
Choi EA, Hope TJ . The role of poly(A) tail stability in the ability of the woodchuck hepatitis virus posttranscriptional regulatory element to stimulate gene expression. Mol Ther 2002; 5: S142 (abstr. 439).
Ill CR et al. Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A. Blood Coagul Fibrinolysis 1997; 8 (Suppl 2): S23–S30.
Hafenrichter DG et al. Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood 1994; 84: 3394–3404.
Ponnazhagan S et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 1997; 190: 203–210.
Sanlioglu S et al. Rate limiting steps of AAV transduction and implications for human gene therapy. Curr Gene Ther 2001; 1: 137–147.
Herzog RW et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56–63.
Gao GP et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854–11859.
Wang L et al. High level expression of canine factor IX in hemophilia B dogs after readministration of AAV2/5 vectors. Mol Ther 2002; 5: S83 (abstr. 250).
Snyder RO, Xiao X, Samulski RJ . Production of recombininant adeno-associated viral vectors. In: Dracapoli NC, Haines JL, Korf BR, Moir DT, Mortan CC, Seidman CE, Seidman JG, Smith DR (eds). Current Protocols in Human Genetics. John Wiley & Sons: New York, 1996.
Acknowledgements
We thank Sandra Powell and Tammy Langer for technical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harding, T., Koprivnikar, K., Tu, G. et al. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B. Gene Ther 11, 204–213 (2004). https://doi.org/10.1038/sj.gt.3302142
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302142
Keywords
This article is cited by
-
Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease
Orphanet Journal of Rare Diseases (2023)
-
Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques
Molecular Therapy - Methods & Clinical Development (2016)
-
Enhancement of the human factor IX expression, mediated by an intron derived fragment from the rat aldolase B gene in cultured hepatoma cells
Biotechnology Letters (2010)
-
Systemic AAV6 Delivery Mediating RNA Interference Against SOD1: Neuromuscular Transduction Does Not Alter Disease Progression in fALS Mice
Molecular Therapy (2008)
-
Large animal models and gene therapy
European Journal of Human Genetics (2006)